TCTR20220511002
Completed
Phase 3
Durability of Immunogenicity and Effectiness of the heterologous COVID-19 vaccination in kidney transplant recipients
ational Council Researach of Thailand0 sites100 target enrollmentMay 11, 2022
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Immunogenicity of the vaccineEffectiveness of the vaccine
- Sponsor
- ational Council Researach of Thailand
- Enrollment
- 100
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients were all recruited from the previous studies (CVIM1, CVIM2, CVIM3 and CVIM 4\)
Exclusion Criteria
- •Those who declined to participate in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Background factors affecting the effectiveness of the COVID-19 vaccine and their association with the microbiomes in the oral cavity and intestinal tractRegardless of the type of diseaseJPRN-UMIN000043558Department of Pulmonology and Gerontology, Graduate School of Medicine, Yamaguchi University180
Not yet recruiting
Not Applicable
Evaluation of safety, effectiveness and duration of immunity after vaccination against Covid-19 in patients with autoimmune rheumatic diseasesspondylitisautoimmune diseasesrheumatoid arthritissystemic lupus erythematosusSjögren's syndromesystemic sclerodermamyositisvasculitisRBR-108fyykdniversidade Federal de São Paulo
Active, not recruiting
Phase 1
Evaluation of How Long Immune Responses to SARS-CoV-2 Persist Following COVID-19 VaccinatioCOVID-19Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2021-000349-42-SESahlgrenska Academy, University of Gothenburg500
Completed
Not Applicable
Investigation of the immunogenicity and durability of second COVID-19 vaccine booster dose and their associations with the background factorsRegardless of the type of diseaseJPRN-UMIN000048396Department of Pulmonology and Gerontology, Graduate School of Medicine, Yamaguchi University100
Active, not recruiting
Not Applicable
Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac® for the season 2009/2010. An open-label, baseline-controlled multi-center study in two groups: adult subjects =18 and =60 years and elderly subjects =61 years of age. - Influvac Annual Update 2009/2010EUCTR2009-010900-27-DESolvay Biologicals BV120